
Compass Pathways PLC
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Stock Performance (90 Days)
Layoff History
Recent News
Other Medical Care Facilities Companies
View All →Frequently Asked Questions
Has COMPASS Pathways plc had layoffs?
How many employees does COMPASS Pathways plc have?
What industry is COMPASS Pathways plc in?
Is COMPASS Pathways plc a publicly traded company?
Where is COMPASS Pathways plc headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.